Literature DB >> 28054573

Inflammation: NSAIDs and cardiovascular risk in arthritis.

Miguel A González-Gay1, Carlos González-Juanatey2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28054573     DOI： 10.1038/nrcardio.2016.208

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  9 in total

1.  Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Authors:  Scott D Solomon; John J V McMurray; Marc A Pfeffer; Janet Wittes; Robert Fowler; Peter Finn; William F Anderson; Ann Zauber; Ernest Hawk; Monica Bertagnolli
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

Review 2.  Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion.

Authors:  María A Martín-Martínez; Carlos González-Juanatey; Santos Castañeda; Javier Llorca; Iván Ferraz-Amaro; Benjamín Fernández-Gutiérrez; Federico Díaz-González; Miguel A González-Gay
Journal:  Semin Arthritis Rheum       Date:  2014-01-24       Impact factor: 5.532

Review 3.  Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers.

Authors:  Raquel López-Mejías; Santos Castañeda; Carlos González-Juanatey; Alfonso Corrales; Iván Ferraz-Amaro; Fernanda Genre; Sara Remuzgo-Martínez; Luis Rodriguez-Rodriguez; Ricardo Blanco; Javier Llorca; Javier Martín; Miguel A González-Gay
Journal:  Autoimmun Rev       Date:  2016-08-01       Impact factor: 9.754

Review 4.  Cardiovascular disease in inflammatory rheumatic diseases.

Authors:  Santos Castañeda; Michael T Nurmohamed; Miguel A González-Gay
Journal:  Best Pract Res Clin Rheumatol       Date:  2016-11-09       Impact factor: 4.098

5.  Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study.

Authors:  Jesper Lindhardsen; Gunnar Hilmar Gislason; Søren Jacobsen; Ole Ahlehoff; Anne-Marie Schjerning Olsen; Ole Rintek Madsen; Christian Torp-Pedersen; Peter Riis Hansen
Journal:  Ann Rheum Dis       Date:  2013-06-08       Impact factor: 19.103

Review 6.  EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Authors:  R Agca; S C Heslinga; S Rollefstad; M Heslinga; I B McInnes; M J L Peters; T K Kvien; M Dougados; H Radner; F Atzeni; J Primdahl; A Södergren; S Wallberg Jonsson; J van Rompay; C Zabalan; T R Pedersen; L Jacobsson; K de Vlam; M A Gonzalez-Gay; A G Semb; G D Kitas; Y M Smulders; Z Szekanecz; N Sattar; D P M Symmons; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2016-10-03       Impact factor: 19.103

7.  Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.

Authors:  Steven E Nissen; Neville D Yeomans; Daniel H Solomon; Thomas F Lüscher; Peter Libby; M Elaine Husni; David Y Graham; Jeffrey S Borer; Lisa M Wisniewski; Katherine E Wolski; Qiuqing Wang; Venu Menon; Frank Ruschitzka; Michael Gaffney; Bruce Beckerman; Manuela F Berger; Weihang Bao; A Michael Lincoff
Journal:  N Engl J Med       Date:  2016-11-13       Impact factor: 91.245

Review 8.  Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).

Authors:  Féline P B Kroon; Lennart R A van der Burg; Sofia Ramiro; Robert B M Landewé; Rachelle Buchbinder; Louise Falzon; Désirée van der Heijde
Journal:  Cochrane Database Syst Rev       Date:  2015-07-17

9.  Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients.

Authors:  N J Goodson; A M Brookhart; D P M Symmons; A J Silman; D H Solomon
Journal:  Ann Rheum Dis       Date:  2008-04-13       Impact factor: 19.103
  9 in total
  2 in total

1.  Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.

Authors:  Mai Duong; Abdelilah Abouelfath; Regis Lassalle; Cécile Droz; Patrick Blin; Nicholas Moore
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

2.  High Serum Cyclophilin C levels as a risk factor marker for Coronary Artery Disease.

Authors:  Amparo Alfonso; Jeremías Bayón; Sandra Gegunde; Eva Alonso; Rebeca Alvariño; Melisa Santás-Álvarez; Ana Testa-Fernández; Ramón Rios-Vázquez; Carlos González-Juanatey; Luis M Botana
Journal:  Sci Rep       Date:  2019-07-22       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.